ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0310

I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study

Amine Mouamnia, Armentieres Hospital Center, Armentieres, France

Meeting: ACR Convergence 2024

Keywords: Comorbidity, Polymyalgia Rheumatica (PMR), prevention, rheumatoid arthritis, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Inflammatory and auto-immune disease are associated to comordities. Indeed, patients suffering from arthritis rheumatoid disease (ARD) such as rheumatoid arthritis (RA), polymyalgia rheumatica (PMR) and spondylarthritis (SA) have an increased risk of cardiovascular diseases, neoplasia, and infectious. We aimed to assess the efficacity of a multidisciplinary program (rheumatologist, cardiovascular, physiotherapist and dietetionnary) in the management of the comorbidities in chronic rheumatism.

Methods: Patients aged over 18, with ARD who were assessed in hospitalization day since 1st January 2023, to 31st December 2023 were included. We excluded patient with gouth and chondrocalcinosis. Assessement was carried out by means of the following criterias: cardiovascular risk factors, vaccinations status (anti-influenza, diphteria-tetanus-polyomyelitis (DTP), anti-pneumoccocal), physical activity, ditetic and osteoporosis. These items were evaluated at the inclusion (M0), at 3 months (M3) and at 6 months (M6).

Results: Of the 54 patients analyzed, 50 patients were inclued. Demographic and clinical characteristics are summarized in table 1. Mean age was 51.4 years old ± 17.1 SD. 6 patients already had a biologic treatment, 46% (n=23) corticosteroids, 50% (n=25) non-streroidal anti-inflammatory drugs. The mean SCORE2 was 2.4. 64% (n=32) patients were not up to date to their vaccination. Only one patient followed the national campagne for the screening of neoplasia (breast, cervitis, colon).

At M3, we observed that 20% (n=10) were engaging physical activity following our recommendations. In addition, 60% (n=30) of patients had adapted their diet in line with the recommendations of the French Society of Rheumatology. 54% (n=27) of patients had undergone an oncological screening. 98% (n=49) of patients were up to date to their vaccines.

At M6, all smokers had reduced their consumption. 41.6% of the smokers had quit smoking. Furthermore, 52% (n=26) of patients were physically active. 74% (n=37) adhered to an adequate diet. 74% (n=37) of patients underwent oncology screening.

Patients suffering from spondylarthritis showed better adherence to the I-CARE program (better control of cardiovascular risk factors, better dietary compliance, higher rate of oncology screening) p< 0.001.

Conclusion: Our study reveals that a systematic screening prevention program leads to a better control of the comorbidities for the patients suffering from ARD and thus even on a short follow-up of 6 months period. This program should be integrated in the management of ARD. Indeed, when patients are awarded of the risk factors, they are quickly modifying their way of life. This program could lead to a decrease of the morbi-mortality in ARD, but to reach this objective, patients should be placed at the heart of the treatment process.

Supporting image 1

Table 1. Demographic and clinical characteristics of patients.


Disclosures: A. Mouamnia: None.

To cite this abstract in AMA style:

Mouamnia A. I-CARE Program: Interest of Multidisciplinary Systematic Screening Program for Comorbidities for Patients Suffering from Arthritis Rheumatoid DiseasE: A Real Life Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/i-care-program-interest-of-multidisciplinary-systematic-screening-program-for-comorbidities-for-patients-suffering-from-arthritis-rheumatoid-disease-a-real-life-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/i-care-program-interest-of-multidisciplinary-systematic-screening-program-for-comorbidities-for-patients-suffering-from-arthritis-rheumatoid-disease-a-real-life-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology